Compositions for treating or preventing cardiovascular disease

• US 20050261257A1
• Filed: 06/03/2005
• Published: 11/24/2005
• Est. Priority Date: 08/30/2002
• Status: Active Grant

• Current Assignee: Nattopharma R&D Limited
• Original Assignee: VitaK BV
• Inventors: Vermeer, Cees
• Granted Patent: US 9,364,447 B2
• Time in Patent Office: Days
• US Class Current: 514/168
• CPC Class Codes: A23L 2/52 Adding ingredients adding preservatives A23L2/44
• CPC Class Codes: A23L 33/15 Vitamins
• CPC Class Codes: A23L 33/155 Vitamins A or D
• CPC Class Codes: A23L 33/16 Inorganic salts, minerals or trace elements
• CPC Class Codes: A23V 2002/00 Food compositions, function of food ingredients or processes for food or foodstuffs
• CPC Class Codes: A23V 2250/1578 Calcium
• CPC Class Codes: A23V 2250/161 Magnesium
• CPC Class Codes: A23V 2250/1642 Zinc
• CPC Class Codes: A23V 2250/7106 Vitamin D3
• CPC Class Codes: A23V 2250/7142 Vitamin K1
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/12 Ketones
• CPC Class Codes: A61K 31/122 having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
• CPC Class Codes: A61K 31/59 Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
• CPC Class Codes: A61K 31/593 9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61P 9/04 Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• CPC Class Codes: A61P 9/12 Antihypertensives
• CPC Class Codes: A61P 9/14 : Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Abstract

Vitamin K is effective in counteracting cardiovascular disorders such as the reduction in arterial elasticity normally associated with the aging process. A pharmaceutical composition or nutritional formulation comprising vitamin K can be used to combat age-related stiffening of the arteries, and the consequences thereof, namely pulmonary congestion, hypertension, left ventricular hypertrophy, congestive (right sided) heart failure, left sided or left ventricular failure, chronic cardiac failure, angina pectoris, myocardial infarction, Mönckeberg'"'"'s sclerosis and stroke. In various embodiments, vitamin K can also be used to reduce or reverse calcification of a blood vessel in pre-existing cardiovascular disorders such as arteriosclerosis.

Claims

1. A method of reducing or reversing calcification of a blood vessel in a mammal suffering from calcification of a blood vessel, comprising administering to the mammal an effective amount of vitamin K to reduce or reverse calcification of the blood vessel.

2. A method according to claim 1, wherein the vitamin K is contained in a pharmaceutical or nutritional formulation.

3. A method according to claim 2, wherein the vitamin K is contained in a food or beverage product or a dietary supplement.

4. A method according to claim 2, wherein the formulation further comprises vitamin D.

5. A method according to claim 1, wherein the calcification is of the tunica media of the aorta or common carotid artery.

6. A method according to claim 1, wherein the vitamin K comprises vitamin K, (phylloquinone), vitamin K₂ (menaquinone) or combination thereof.

7. A method according to claim 1, wherein the daily dosage of vitamin K is 50μ

g-2000 μ

g.

8. A method according to claim 4, wherein the vitamin D is vitamin D₃ (cholecalciferol).

9. A method according to claim 1, wherein the mammal is a human.

10. A method of treating a human suffering from arteriosclerosis caused by calcification of a blood vessel, comprising administering to the human an effective amount of vitamin K to reduce or reverse calcification of the blood vessel.

11. A method according to claim 10, wherein the vitamin K comprises a pharmaceutical or nutritional formulation.

12. A method according to claim 10, wherein the vitamin K is contained in a food or beverage product or a dietary supplement.

13. A method according to claim 11, wherein the formulation further comprises vitamin D.

14. A method according to claim 10, wherein the calcification is of the tunica media of the aorta or common carotid artery.

15. A method according to claim 10, wherein the vitamin K comprises vitamin K₁ (phylloquinone), vitamin K₂ (menaquinone) or combination thereof.

16. A method according to claim 10, wherein the daily dosage of vitamin K is 50 μ

g-2000 μ

g.

17. A method according to claim 13, wherein the vitamin D is vitamin D₃ (cholecalciferol).

18. A composition for reducing or reversing calcification of a blood vessel in a human, comprising 50 μ

g-2000 μ

g of vitamin K.

19. A composition according to claim 18 further comprising at least one:

polyphenol, vitamin C, vitamin E, L-Arginine, phytosterol, antihypertensive peptide, soluble fiber, omega-3, omega-6, omega-9 fatty acid(s), carnitine, taurine, coenzyme Q10, creatine, folic acid, folates, magnesium, potassium, vitamin B6, vitamin B12; and

vitamin D.

20. A composition according to claim 18, wherein the composition is a food or beverage product or a dietary supplement.